InThera Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Seed

  • Investors
  • 4

InThera General Information

Description

Developer of therapeutic vaccines designed to treat infectious diseases. The company offers recombinant proteins and virus-like particle vaccines using E. coli-based VLP technology to improve wellness through innovative protein biotechnology, enabling medical professionals to treat norovirus, hand, foot, and mouth disease virus.

Contact Information

Website
inthera.co.kr
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • B-218, 11, Beobwon-ro 11-gil
  • Songpa-gu
  • Seoul
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • B-218, 11, Beobwon-ro 11-gil
  • Songpa-gu
  • Seoul
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

InThera Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Seed Round 01-May-2023 Completed Clinical Trials - Phase 1
2. Accelerator/Incubator 14-Sep-2018 Completed Clinical Trials - Phase 1
1. Accelerator/Incubator 01-Jun-2017 Completed Clinical Trials - Phase 1
To view InThera’s complete valuation and funding history, request access »

InThera Patents

InThera Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024251398-A1 Recombinant expression vector for production of virus-like particle-based multivalent norovirus vaccine and manufacturing method therefor Pending 14-Apr-2023
EP-4696702-A1 Recombinant expression vector for production of virus-like particle-based multivalent norovirus vaccine and manufacturing method therefor Pending 14-Apr-2023
US-20260284173-A1 Recombinant expression vector for production of virus-like particle-based multivalent norovirus vaccine and manufacturing method therefor Pending 14-Apr-2023
WO-2024215140-A1 Recombinant expression vector for production of virus-like particle-based multivalent norovirus vaccine and manufacturing method therefor Inactive 14-Apr-2023
AU-2021282837-A1 Recombinant expression vector for producing encapsulin-based vaccine, and preparation method therefor Active 01-Jun-2020 A61P31/12
To view InThera’s complete patent history, request access »

InThera Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

InThera Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
GeneN Investment Partners Venture Capital Minority
InterVest Venture Capital Minority
Tech Incubator Program for Startup Accelerator/Incubator
Bluepoint Venture Capital Minority
To view InThera’s complete investors history, request access »

InThera FAQs

  • When was InThera founded?

    InThera was founded in 2016.

  • Where is InThera headquartered?

    InThera is headquartered in Seoul, South Korea.

  • What is the size of InThera?

    InThera has 13 total employees.

  • What industry is InThera in?

    InThera’s primary industry is Drug Discovery.

  • Is InThera a private or public company?

    InThera is a Private company.

  • What is InThera’s current revenue?

    The current revenue for InThera is .

  • How much funding has InThera raised over time?

    InThera has raised $446K.

  • Who are InThera’s investors?

    GeneN Investment Partners, InterVest, Tech Incubator Program for Startup, and Bluepoint have invested in InThera.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process